Lake Street analyst Eric Martinuzzi raised the firm’s price target on Cellebrite (CLBT) to $26 from $21 and keeps a Buy rating on the shares. Cellebrite’s “strong guide” prompts the firm to raise estimates for both Q1 and 2025, the analyst tells investors. The firm views the post-earnings pullback in shares as a buying opportunity, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite price target raised to $30 from $25 at TD Cowen
- Cellebrite Reports Strong Growth in 2024 Earnings
- Strategic Initiatives and Long-term Growth Drive Buy Rating for Cellebrite DI
- Cellebrite Achieves Strong 2024 Financial Performance with Significant ARR Growth
- Cellebrite reports Q4 EPS 10c, consensus 10c